



TSD Japan

Press Release

No.005

October 28, 2008

TSD Japan, Inc.(Osaka, Japan)
Yoshiharu Sakashita, CEO

Announcement of New Shares by Third Party Allocation

TSD Japan, Inc.("TSD") is pleased to announce that it has completed the issuance of new stock by third party allocation in the amount of 800,220,000 yen. The financing was mainly led by venture capitals, Daiwa SMBC Capital Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., COLLABO SANGAKUKAN, Sansei Capital Investment Co., Ltd., Osaka Small and Medium Business Investment & Consultation Co., Ltd, IkeGin Capital Co., Ltd, Bio-Sight Capital, Inc. and a business corporation, AnGes MG, Inc.

We believe their decision on investing in TSD despite the severe situation surrounding pharmaceutical venture companies came from their recognition and expectations toward our business. Therefore, we will commit to make our best efforts to fulfill their expectations by steadily expanding business.

The funds will be allocated for development of COLAL-PRED®, treatment for ulcerative colitis, and HVJ-E, anti-prostate cancer agent.

< Corporate Profile >

TSD Japan, Inc.	
Head Office	: 1-15-2 Nishinakajima, Yodogawa-ku, Osaka, Japan
President & CEO	: Yoshiharu Sakashita
Date Established	: July 2005
Capital Stock	: 734 million yen (as of October 28, 2008)
Main Business	: 1. Value-added type partnering business to assist partnering between domestic and foreign bio-venture companies and pharmaceutical companies in Japan 2. Contract clinical studies service (CRO Business)

For more information please contact:

TSD Japan, Inc.

1-15-2 Nishinakajima, Yodogawa-ku, Osaka

TEL +81-6-6309-5200 FAX +81-6-6309-5203